(Q46033801)

English

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

scientific article published in July 2009

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

0 references

Marc-Oliver Grimm

object named as

Marc-Oliver Grimm

4

0 references

Philippe Beuzeboc

7

object named as

Philippe Beuzeboc

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

author name string

Christian Wülfing

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

Jean-Pascal H Machiels

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

Dirk J Richel

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

Uwe Treiber

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

Marco R De Groot

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

Roma Parikh

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

Frank Pétavy

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

Iman A El-Hariry

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

language of work or name

0 references

publication date

1 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

number of pages

10

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

115

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

13

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

2881-2890

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

21 January 2018

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic chemotherapy for advanced bladder cancer: update and controversies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic chemotherapy in locally advanced and/or metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Update on chemotherapy for advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

The systemic treatment of advanced and metastatic bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for metastatic or unresectable bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of metastatic bladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth factors and receptors as prognostic markers in urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

The emerging role of lapatinib in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Planned versus attained design in phase II clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

State-of-the-art management of metastatic disease at initial presentation or recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel agents for muscle-invasive and advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24337

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.24337

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19399906

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46033801&oldid=1779528893"